UCB was a new entrant among the top 20 biopharmaceutical companies, doubling its market capitalisation from $16.9bn in 2023 to $38.7bn in 2024. Source: GlobalData, Pharma Intelligence Center; Stock ...

Brian Feth, Jonathan Grinstein, PhD, Beth Willers, and Laks Pernenkil go behind the headlines to discuss major news announcements made during the JP Morgan Healthcare Conference, a wave of new ...

Will competition from China put pressure on young U.S. drugmakers? The answers will shape the industry’s fortunes this year, as BioPharma Dive details in the stories below. Read on for a look at ...

and SHANGHAI, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP) a clinical-stage company dedicated to accelerating the global development of ...

We would like to share some important news with you. After years of bringing you the latest insights, analysis and innovation news from the pharma industries, we have made the difficult decision to ...

Will 2025 herald a sudden turnaround for biopharma? Unlikely, but continued recovery is likely with some strong growth in therapy areas including cancer, diabetes and – inevitably – obesity. Four of ...

Tanvex BioPharma, Inc. ("Tanvex"), a contract development and manufacturing organization (CDMO) for biologics and a biosimilars products company, is pleased to announce the successful completion ...

Following the strange year for the biopharma industry that was 2024, insiders and analysts alike are waiting expectantly to see how trends in layoffs, drug shortages, clinical trials and more play ...

Biopharma executives make their predictions for the year ahead, from a bold forecast for the return of the megadeal to a plea for the slow, healthy recovery of the industry at large. The J.P. Morgan ...

The flurry of M&A deals at the conference may signal an M&A uptick in 2025. Credit: R Photography Background via Shutterstock. The first day of the JP Morgan Healthcare Conference held in San ...

SAN FRANCISCO — The J.P. Morgan Healthcare Conference isn’t just a venue for companies in the industry to outline their plans for the year or tamp down questions about their finances.